nodes	percent_of_prediction	percent_of_DWPC	metapath
Iloperidone—HTR7—vas deferens—urinary bladder cancer	0.0493	0.223	CbGeAlD
Iloperidone—CYP3A4—Thiotepa—urinary bladder cancer	0.0363	0.224	CbGbCtD
Iloperidone—CYP2E1—Etoposide—urinary bladder cancer	0.0324	0.2	CbGbCtD
Iloperidone—CYP3A5—Etoposide—urinary bladder cancer	0.0252	0.155	CbGbCtD
Iloperidone—CYP1A2—Fluorouracil—urinary bladder cancer	0.0225	0.139	CbGbCtD
Iloperidone—CYP1A2—Etoposide—urinary bladder cancer	0.0188	0.116	CbGbCtD
Iloperidone—CYP2D6—Doxorubicin—urinary bladder cancer	0.0105	0.065	CbGbCtD
Iloperidone—CYP3A4—Etoposide—urinary bladder cancer	0.00983	0.0606	CbGbCtD
Iloperidone—CYP1A2—urine—urinary bladder cancer	0.00977	0.0442	CbGeAlD
Iloperidone—CYP2E1—urine—urinary bladder cancer	0.00879	0.0397	CbGeAlD
Iloperidone—HTR2A—urine—urinary bladder cancer	0.00764	0.0345	CbGeAlD
Iloperidone—CYP3A4—urine—urinary bladder cancer	0.00707	0.032	CbGeAlD
Iloperidone—CYP2D6—urine—urinary bladder cancer	0.00696	0.0315	CbGeAlD
Iloperidone—CYP3A4—Doxorubicin—urinary bladder cancer	0.00671	0.0413	CbGbCtD
Iloperidone—SIGMAR1—prostate gland—urinary bladder cancer	0.00515	0.0233	CbGeAlD
Iloperidone—SIGMAR1—seminal vesicle—urinary bladder cancer	0.00435	0.0197	CbGeAlD
Iloperidone—ADRA1A—prostate gland—urinary bladder cancer	0.00424	0.0192	CbGeAlD
Iloperidone—ADRA2C—prostate gland—urinary bladder cancer	0.00404	0.0183	CbGeAlD
Iloperidone—SIGMAR1—smooth muscle tissue—urinary bladder cancer	0.00365	0.0165	CbGeAlD
Iloperidone—SIGMAR1—urethra—urinary bladder cancer	0.00345	0.0156	CbGeAlD
Iloperidone—ADRA2C—seminal vesicle—urinary bladder cancer	0.00342	0.0155	CbGeAlD
Iloperidone—CYP3A5—prostate gland—urinary bladder cancer	0.00338	0.0153	CbGeAlD
Iloperidone—HRH1—prostate gland—urinary bladder cancer	0.00328	0.0148	CbGeAlD
Iloperidone—HTR7—epithelium—urinary bladder cancer	0.00323	0.0146	CbGeAlD
Iloperidone—ADRA2A—prostate gland—urinary bladder cancer	0.00323	0.0146	CbGeAlD
Iloperidone—CYP2E1—prostate gland—urinary bladder cancer	0.00316	0.0143	CbGeAlD
Iloperidone—HTR1A—renal system—urinary bladder cancer	0.00314	0.0142	CbGeAlD
Iloperidone—ADRA1A—epithelium—urinary bladder cancer	0.00312	0.0141	CbGeAlD
Iloperidone—HTR7—smooth muscle tissue—urinary bladder cancer	0.00311	0.0141	CbGeAlD
Iloperidone—HTR1D—female reproductive system—urinary bladder cancer	0.00301	0.0136	CbGeAlD
Iloperidone—HTR7—renal system—urinary bladder cancer	0.003	0.0136	CbGeAlD
Iloperidone—HTR2C—female reproductive system—urinary bladder cancer	0.00298	0.0135	CbGeAlD
Iloperidone—ADRA1A—renal system—urinary bladder cancer	0.00289	0.0131	CbGeAlD
Iloperidone—Gefitinib—EGFR—urinary bladder cancer	0.00276	1	CrCbGaD
Iloperidone—ADRA2C—renal system—urinary bladder cancer	0.00276	0.0125	CbGeAlD
Iloperidone—ADRA2A—seminal vesicle—urinary bladder cancer	0.00273	0.0123	CbGeAlD
Iloperidone—ADRA2C—urethra—urinary bladder cancer	0.00271	0.0122	CbGeAlD
Iloperidone—CYP2E1—seminal vesicle—urinary bladder cancer	0.00267	0.0121	CbGeAlD
Iloperidone—SIGMAR1—vagina—urinary bladder cancer	0.00254	0.0115	CbGeAlD
Iloperidone—HRH1—epithelium—urinary bladder cancer	0.00241	0.0109	CbGeAlD
Iloperidone—HTR7—female reproductive system—urinary bladder cancer	0.0024	0.0109	CbGeAlD
Iloperidone—CYP1A2—renal system—urinary bladder cancer	0.00239	0.0108	CbGeAlD
Iloperidone—HRH1—smooth muscle tissue—urinary bladder cancer	0.00233	0.0105	CbGeAlD
Iloperidone—CYP3A5—renal system—urinary bladder cancer	0.00231	0.0104	CbGeAlD
Iloperidone—HRH1—urethra—urinary bladder cancer	0.0022	0.00994	CbGeAlD
Iloperidone—ADRA2A—urethra—urinary bladder cancer	0.00216	0.00976	CbGeAlD
Iloperidone—CYP2E1—renal system—urinary bladder cancer	0.00215	0.00972	CbGeAlD
Iloperidone—CYP2E1—urethra—urinary bladder cancer	0.00211	0.00955	CbGeAlD
Iloperidone—HTR2A—epithelium—urinary bladder cancer	0.00202	0.00911	CbGeAlD
Iloperidone—ADRA2C—vagina—urinary bladder cancer	0.002	0.00902	CbGeAlD
Iloperidone—HTR2A—smooth muscle tissue—urinary bladder cancer	0.00194	0.00878	CbGeAlD
Iloperidone—HTR2A—renal system—urinary bladder cancer	0.00187	0.00845	CbGeAlD
Iloperidone—HRH1—female reproductive system—urinary bladder cancer	0.00179	0.0081	CbGeAlD
Iloperidone—ADRA2A—female reproductive system—urinary bladder cancer	0.00176	0.00796	CbGeAlD
Iloperidone—CYP3A4—renal system—urinary bladder cancer	0.00173	0.00782	CbGeAlD
Iloperidone—CYP2E1—female reproductive system—urinary bladder cancer	0.00172	0.00779	CbGeAlD
Iloperidone—CYP2D6—renal system—urinary bladder cancer	0.0017	0.0077	CbGeAlD
Iloperidone—CYP3A5—vagina—urinary bladder cancer	0.00167	0.00755	CbGeAlD
Iloperidone—SIGMAR1—lymph node—urinary bladder cancer	0.00164	0.00743	CbGeAlD
Iloperidone—HRH1—vagina—urinary bladder cancer	0.00162	0.00733	CbGeAlD
Iloperidone—ADRA2A—vagina—urinary bladder cancer	0.00159	0.0072	CbGeAlD
Iloperidone—HTR2A—female reproductive system—urinary bladder cancer	0.0015	0.00677	CbGeAlD
Iloperidone—CYP3A4—female reproductive system—urinary bladder cancer	0.00139	0.00627	CbGeAlD
Iloperidone—CYP2D6—female reproductive system—urinary bladder cancer	0.00136	0.00617	CbGeAlD
Iloperidone—HTR2A—vagina—urinary bladder cancer	0.00135	0.00612	CbGeAlD
Iloperidone—ADRA2C—lymph node—urinary bladder cancer	0.00129	0.00584	CbGeAlD
Iloperidone—HRH1—lymph node—urinary bladder cancer	0.00105	0.00474	CbGeAlD
Iloperidone—ADRA2A—lymph node—urinary bladder cancer	0.00103	0.00466	CbGeAlD
Iloperidone—Leukopenia—Cisplatin—urinary bladder cancer	0.000901	0.00199	CcSEcCtD
Iloperidone—Muscle spasms—Etoposide—urinary bladder cancer	0.000887	0.00196	CcSEcCtD
Iloperidone—Oedema—Gemcitabine—urinary bladder cancer	0.000881	0.00195	CcSEcCtD
Iloperidone—Cardiac failure—Epirubicin—urinary bladder cancer	0.00088	0.00195	CcSEcCtD
Iloperidone—Lethargy—Epirubicin—urinary bladder cancer	0.000876	0.00194	CcSEcCtD
Iloperidone—Infection—Gemcitabine—urinary bladder cancer	0.000876	0.00194	CcSEcCtD
Iloperidone—Confusional state—Fluorouracil—urinary bladder cancer	0.000874	0.00193	CcSEcCtD
Iloperidone—Mood swings—Methotrexate—urinary bladder cancer	0.000869	0.00192	CcSEcCtD
Iloperidone—Oedema—Fluorouracil—urinary bladder cancer	0.000867	0.00192	CcSEcCtD
Iloperidone—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000864	0.00191	CcSEcCtD
Iloperidone—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000863	0.00191	CcSEcCtD
Iloperidone—Infection—Fluorouracil—urinary bladder cancer	0.000861	0.0019	CcSEcCtD
Iloperidone—Renal failure acute—Doxorubicin—urinary bladder cancer	0.00086	0.0019	CcSEcCtD
Iloperidone—Myalgia—Cisplatin—urinary bladder cancer	0.000857	0.0019	CcSEcCtD
Iloperidone—Anaemia—Etoposide—urinary bladder cancer	0.000852	0.00189	CcSEcCtD
Iloperidone—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00085	0.00188	CcSEcCtD
Iloperidone—Tachycardia—Fluorouracil—urinary bladder cancer	0.000846	0.00187	CcSEcCtD
Iloperidone—Increased appetite—Doxorubicin—urinary bladder cancer	0.000845	0.00187	CcSEcCtD
Iloperidone—Affect lability—Epirubicin—urinary bladder cancer	0.000845	0.00187	CcSEcCtD
Iloperidone—Breast disorder—Methotrexate—urinary bladder cancer	0.000829	0.00183	CcSEcCtD
Iloperidone—Vertigo—Etoposide—urinary bladder cancer	0.000829	0.00183	CcSEcCtD
Iloperidone—Body temperature increased—Thiotepa—urinary bladder cancer	0.000828	0.00183	CcSEcCtD
Iloperidone—Leukopenia—Etoposide—urinary bladder cancer	0.000826	0.00183	CcSEcCtD
Iloperidone—Hypotension—Gemcitabine—urinary bladder cancer	0.000824	0.00182	CcSEcCtD
Iloperidone—Oedema—Cisplatin—urinary bladder cancer	0.000822	0.00182	CcSEcCtD
Iloperidone—Infection—Cisplatin—urinary bladder cancer	0.000816	0.00181	CcSEcCtD
Iloperidone—Cardiac failure—Doxorubicin—urinary bladder cancer	0.000814	0.0018	CcSEcCtD
Iloperidone—Mood swings—Epirubicin—urinary bladder cancer	0.000813	0.0018	CcSEcCtD
Iloperidone—Lethargy—Doxorubicin—urinary bladder cancer	0.000811	0.00179	CcSEcCtD
Iloperidone—Hypotension—Fluorouracil—urinary bladder cancer	0.00081	0.00179	CcSEcCtD
Iloperidone—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000806	0.00178	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000803	0.00178	CcSEcCtD
Iloperidone—Tachycardia—Cisplatin—urinary bladder cancer	0.000802	0.00177	CcSEcCtD
Iloperidone—Dehydration—Epirubicin—urinary bladder cancer	0.000798	0.00177	CcSEcCtD
Iloperidone—Asthma—Methotrexate—urinary bladder cancer	0.000793	0.00175	CcSEcCtD
Iloperidone—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000791	0.00175	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.00079	0.00175	CcSEcCtD
Iloperidone—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000786	0.00174	CcSEcCtD
Iloperidone—Orthostatic hypotension—Epirubicin—urinary bladder cancer	0.000784	0.00173	CcSEcCtD
Iloperidone—Somnolence—Gemcitabine—urinary bladder cancer	0.000784	0.00173	CcSEcCtD
Iloperidone—Affect lability—Doxorubicin—urinary bladder cancer	0.000782	0.00173	CcSEcCtD
Iloperidone—Hypokalaemia—Epirubicin—urinary bladder cancer	0.000781	0.00173	CcSEcCtD
Iloperidone—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000778	0.00172	CcSEcCtD
Iloperidone—Breast disorder—Epirubicin—urinary bladder cancer	0.000776	0.00172	CcSEcCtD
Iloperidone—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000773	0.00171	CcSEcCtD
Iloperidone—Somnolence—Fluorouracil—urinary bladder cancer	0.00077	0.0017	CcSEcCtD
Iloperidone—Hypotension—Cisplatin—urinary bladder cancer	0.000768	0.0017	CcSEcCtD
Iloperidone—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.000768	0.0017	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000761	0.00168	CcSEcCtD
Iloperidone—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.00076	0.00168	CcSEcCtD
Iloperidone—Fatigue—Gemcitabine—urinary bladder cancer	0.00076	0.00168	CcSEcCtD
Iloperidone—Gastritis—Epirubicin—urinary bladder cancer	0.00076	0.00168	CcSEcCtD
Iloperidone—Confusional state—Etoposide—urinary bladder cancer	0.000759	0.00168	CcSEcCtD
Iloperidone—Mood swings—Doxorubicin—urinary bladder cancer	0.000752	0.00166	CcSEcCtD
Iloperidone—Asthenia—Thiotepa—urinary bladder cancer	0.000752	0.00166	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000749	0.00166	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000748	0.00165	CcSEcCtD
Iloperidone—Infection—Etoposide—urinary bladder cancer	0.000748	0.00165	CcSEcCtD
Iloperidone—Asthma—Epirubicin—urinary bladder cancer	0.000742	0.00164	CcSEcCtD
Iloperidone—Dysuria—Methotrexate—urinary bladder cancer	0.000741	0.00164	CcSEcCtD
Iloperidone—Dehydration—Doxorubicin—urinary bladder cancer	0.000739	0.00163	CcSEcCtD
Iloperidone—Paraesthesia—Cisplatin—urinary bladder cancer	0.000738	0.00163	CcSEcCtD
Iloperidone—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000737	0.00163	CcSEcCtD
Iloperidone—Tachycardia—Etoposide—urinary bladder cancer	0.000735	0.00162	CcSEcCtD
Iloperidone—Dyspnoea—Cisplatin—urinary bladder cancer	0.000732	0.00162	CcSEcCtD
Iloperidone—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.00073	0.00162	CcSEcCtD
Iloperidone—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000726	0.00161	CcSEcCtD
Iloperidone—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.000725	0.0016	CcSEcCtD
Iloperidone—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.000723	0.0016	CcSEcCtD
Iloperidone—Breast disorder—Doxorubicin—urinary bladder cancer	0.000718	0.00159	CcSEcCtD
Iloperidone—Diarrhoea—Thiotepa—urinary bladder cancer	0.000717	0.00159	CcSEcCtD
Iloperidone—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000714	0.00158	CcSEcCtD
Iloperidone—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.00071	0.00157	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000709	0.00157	CcSEcCtD
Iloperidone—Hypotension—Etoposide—urinary bladder cancer	0.000703	0.00156	CcSEcCtD
Iloperidone—Gastritis—Doxorubicin—urinary bladder cancer	0.000703	0.00155	CcSEcCtD
Iloperidone—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000697	0.00154	CcSEcCtD
Iloperidone—Dysuria—Epirubicin—urinary bladder cancer	0.000694	0.00153	CcSEcCtD
Iloperidone—Dizziness—Thiotepa—urinary bladder cancer	0.000693	0.00153	CcSEcCtD
Iloperidone—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.00069	0.00153	CcSEcCtD
Iloperidone—Stomatitis—Methotrexate—urinary bladder cancer	0.000689	0.00152	CcSEcCtD
Iloperidone—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000687	0.00152	CcSEcCtD
Iloperidone—Asthma—Doxorubicin—urinary bladder cancer	0.000686	0.00152	CcSEcCtD
Iloperidone—Pollakiuria—Epirubicin—urinary bladder cancer	0.000685	0.00152	CcSEcCtD
Iloperidone—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000685	0.00152	CcSEcCtD
Iloperidone—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000677	0.0015	CcSEcCtD
Iloperidone—Paraesthesia—Etoposide—urinary bladder cancer	0.000676	0.00149	CcSEcCtD
Iloperidone—Weight increased—Epirubicin—urinary bladder cancer	0.000675	0.00149	CcSEcCtD
Iloperidone—Weight decreased—Epirubicin—urinary bladder cancer	0.000671	0.00148	CcSEcCtD
Iloperidone—Dyspnoea—Etoposide—urinary bladder cancer	0.000671	0.00148	CcSEcCtD
Iloperidone—Somnolence—Etoposide—urinary bladder cancer	0.000669	0.00148	CcSEcCtD
Iloperidone—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000669	0.00148	CcSEcCtD
Iloperidone—Epistaxis—Methotrexate—urinary bladder cancer	0.000667	0.00147	CcSEcCtD
Iloperidone—Rash—Thiotepa—urinary bladder cancer	0.000661	0.00146	CcSEcCtD
Iloperidone—Dermatitis—Thiotepa—urinary bladder cancer	0.00066	0.00146	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00065	0.00144	CcSEcCtD
Iloperidone—Body temperature increased—Cisplatin—urinary bladder cancer	0.000649	0.00144	CcSEcCtD
Iloperidone—Fatigue—Etoposide—urinary bladder cancer	0.000649	0.00144	CcSEcCtD
Iloperidone—Stomatitis—Epirubicin—urinary bladder cancer	0.000645	0.00143	CcSEcCtD
Iloperidone—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000643	0.00142	CcSEcCtD
Iloperidone—Dysuria—Doxorubicin—urinary bladder cancer	0.000642	0.00142	CcSEcCtD
Iloperidone—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000638	0.00141	CcSEcCtD
Iloperidone—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000634	0.0014	CcSEcCtD
Iloperidone—Asthenia—Gemcitabine—urinary bladder cancer	0.000632	0.0014	CcSEcCtD
Iloperidone—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000627	0.00139	CcSEcCtD
Iloperidone—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000626	0.00138	CcSEcCtD
Iloperidone—Weight increased—Doxorubicin—urinary bladder cancer	0.000625	0.00138	CcSEcCtD
Iloperidone—Epistaxis—Epirubicin—urinary bladder cancer	0.000624	0.00138	CcSEcCtD
Iloperidone—Nausea—Thiotepa—urinary bladder cancer	0.000622	0.00138	CcSEcCtD
Iloperidone—Urethral disorder—Methotrexate—urinary bladder cancer	0.000622	0.00138	CcSEcCtD
Iloperidone—Weight decreased—Doxorubicin—urinary bladder cancer	0.000621	0.00137	CcSEcCtD
Iloperidone—Feeling abnormal—Etoposide—urinary bladder cancer	0.00062	0.00137	CcSEcCtD
Iloperidone—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000603	0.00133	CcSEcCtD
Iloperidone—Stomatitis—Doxorubicin—urinary bladder cancer	0.000597	0.00132	CcSEcCtD
Iloperidone—Body temperature increased—Etoposide—urinary bladder cancer	0.000595	0.00132	CcSEcCtD
Iloperidone—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000595	0.00132	CcSEcCtD
Iloperidone—Eye disorder—Methotrexate—urinary bladder cancer	0.000593	0.00131	CcSEcCtD
Iloperidone—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000593	0.00131	CcSEcCtD
Iloperidone—Tinnitus—Methotrexate—urinary bladder cancer	0.000592	0.00131	CcSEcCtD
Iloperidone—Asthenia—Cisplatin—urinary bladder cancer	0.000589	0.0013	CcSEcCtD
Iloperidone—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000589	0.0013	CcSEcCtD
Iloperidone—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000586	0.0013	CcSEcCtD
Iloperidone—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000584	0.00129	CcSEcCtD
Iloperidone—Urethral disorder—Epirubicin—urinary bladder cancer	0.000582	0.00129	CcSEcCtD
Iloperidone—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000579	0.00128	CcSEcCtD
Iloperidone—Epistaxis—Doxorubicin—urinary bladder cancer	0.000577	0.00128	CcSEcCtD
Iloperidone—Angiopathy—Methotrexate—urinary bladder cancer	0.000576	0.00127	CcSEcCtD
Iloperidone—Dizziness—Fluorouracil—urinary bladder cancer	0.000573	0.00127	CcSEcCtD
Iloperidone—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000572	0.00126	CcSEcCtD
Iloperidone—Diarrhoea—Cisplatin—urinary bladder cancer	0.000562	0.00124	CcSEcCtD
Iloperidone—Mental disorder—Methotrexate—urinary bladder cancer	0.000556	0.00123	CcSEcCtD
Iloperidone—Rash—Gemcitabine—urinary bladder cancer	0.000556	0.00123	CcSEcCtD
Iloperidone—Dermatitis—Gemcitabine—urinary bladder cancer	0.000555	0.00123	CcSEcCtD
Iloperidone—Eye disorder—Epirubicin—urinary bladder cancer	0.000555	0.00123	CcSEcCtD
Iloperidone—Tinnitus—Epirubicin—urinary bladder cancer	0.000554	0.00122	CcSEcCtD
Iloperidone—Malnutrition—Methotrexate—urinary bladder cancer	0.000552	0.00122	CcSEcCtD
Iloperidone—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000551	0.00122	CcSEcCtD
Iloperidone—Rash—Fluorouracil—urinary bladder cancer	0.000546	0.00121	CcSEcCtD
Iloperidone—Dermatitis—Fluorouracil—urinary bladder cancer	0.000546	0.00121	CcSEcCtD
Iloperidone—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000543	0.0012	CcSEcCtD
Iloperidone—Asthenia—Etoposide—urinary bladder cancer	0.00054	0.00119	CcSEcCtD
Iloperidone—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.00054	0.00119	CcSEcCtD
Iloperidone—Angiopathy—Epirubicin—urinary bladder cancer	0.000539	0.00119	CcSEcCtD
Iloperidone—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000539	0.00119	CcSEcCtD
Iloperidone—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000535	0.00118	CcSEcCtD
Iloperidone—Arrhythmia—Epirubicin—urinary bladder cancer	0.000531	0.00117	CcSEcCtD
Iloperidone—Nausea—Gemcitabine—urinary bladder cancer	0.000524	0.00116	CcSEcCtD
Iloperidone—Vision blurred—Methotrexate—urinary bladder cancer	0.000521	0.00115	CcSEcCtD
Iloperidone—Mental disorder—Epirubicin—urinary bladder cancer	0.00052	0.00115	CcSEcCtD
Iloperidone—Rash—Cisplatin—urinary bladder cancer	0.000518	0.00115	CcSEcCtD
Iloperidone—Dermatitis—Cisplatin—urinary bladder cancer	0.000518	0.00114	CcSEcCtD
Iloperidone—Malnutrition—Epirubicin—urinary bladder cancer	0.000517	0.00114	CcSEcCtD
Iloperidone—Diarrhoea—Etoposide—urinary bladder cancer	0.000515	0.00114	CcSEcCtD
Iloperidone—Nausea—Fluorouracil—urinary bladder cancer	0.000515	0.00114	CcSEcCtD
Iloperidone—Eye disorder—Doxorubicin—urinary bladder cancer	0.000514	0.00114	CcSEcCtD
Iloperidone—Tinnitus—Doxorubicin—urinary bladder cancer	0.000512	0.00113	CcSEcCtD
Iloperidone—Anaemia—Methotrexate—urinary bladder cancer	0.000511	0.00113	CcSEcCtD
Iloperidone—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.00051	0.00113	CcSEcCtD
Iloperidone—Angiopathy—Doxorubicin—urinary bladder cancer	0.000499	0.0011	CcSEcCtD
Iloperidone—Dizziness—Etoposide—urinary bladder cancer	0.000498	0.0011	CcSEcCtD
Iloperidone—Muscle spasms—Epirubicin—urinary bladder cancer	0.000497	0.0011	CcSEcCtD
Iloperidone—Vertigo—Methotrexate—urinary bladder cancer	0.000496	0.0011	CcSEcCtD
Iloperidone—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000495	0.0011	CcSEcCtD
Iloperidone—Leukopenia—Methotrexate—urinary bladder cancer	0.000494	0.00109	CcSEcCtD
Iloperidone—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000491	0.00109	CcSEcCtD
Iloperidone—Nausea—Cisplatin—urinary bladder cancer	0.000488	0.00108	CcSEcCtD
Iloperidone—Vision blurred—Epirubicin—urinary bladder cancer	0.000487	0.00108	CcSEcCtD
Iloperidone—Mental disorder—Doxorubicin—urinary bladder cancer	0.000481	0.00106	CcSEcCtD
Iloperidone—Malnutrition—Doxorubicin—urinary bladder cancer	0.000478	0.00106	CcSEcCtD
Iloperidone—Anaemia—Epirubicin—urinary bladder cancer	0.000478	0.00106	CcSEcCtD
Iloperidone—Agitation—Epirubicin—urinary bladder cancer	0.000475	0.00105	CcSEcCtD
Iloperidone—Rash—Etoposide—urinary bladder cancer	0.000475	0.00105	CcSEcCtD
Iloperidone—Dermatitis—Etoposide—urinary bladder cancer	0.000474	0.00105	CcSEcCtD
Iloperidone—Arthralgia—Methotrexate—urinary bladder cancer	0.00047	0.00104	CcSEcCtD
Iloperidone—Myalgia—Methotrexate—urinary bladder cancer	0.00047	0.00104	CcSEcCtD
Iloperidone—Vertigo—Epirubicin—urinary bladder cancer	0.000464	0.00103	CcSEcCtD
Iloperidone—Leukopenia—Epirubicin—urinary bladder cancer	0.000463	0.00102	CcSEcCtD
Iloperidone—Muscle spasms—Doxorubicin—urinary bladder cancer	0.00046	0.00102	CcSEcCtD
Iloperidone—Palpitations—Epirubicin—urinary bladder cancer	0.000457	0.00101	CcSEcCtD
Iloperidone—Confusional state—Methotrexate—urinary bladder cancer	0.000455	0.00101	CcSEcCtD
Iloperidone—Vision blurred—Doxorubicin—urinary bladder cancer	0.000451	0.000997	CcSEcCtD
Iloperidone—Infection—Methotrexate—urinary bladder cancer	0.000448	0.000991	CcSEcCtD
Iloperidone—Nausea—Etoposide—urinary bladder cancer	0.000447	0.000989	CcSEcCtD
Iloperidone—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000442	0.000978	CcSEcCtD
Iloperidone—Anaemia—Doxorubicin—urinary bladder cancer	0.000442	0.000978	CcSEcCtD
Iloperidone—Arthralgia—Epirubicin—urinary bladder cancer	0.00044	0.000973	CcSEcCtD
Iloperidone—Myalgia—Epirubicin—urinary bladder cancer	0.00044	0.000973	CcSEcCtD
Iloperidone—Agitation—Doxorubicin—urinary bladder cancer	0.00044	0.000972	CcSEcCtD
Iloperidone—Dry mouth—Epirubicin—urinary bladder cancer	0.00043	0.000952	CcSEcCtD
Iloperidone—Vertigo—Doxorubicin—urinary bladder cancer	0.00043	0.000951	CcSEcCtD
Iloperidone—Leukopenia—Doxorubicin—urinary bladder cancer	0.000428	0.000947	CcSEcCtD
Iloperidone—Confusional state—Epirubicin—urinary bladder cancer	0.000425	0.000941	CcSEcCtD
Iloperidone—Palpitations—Doxorubicin—urinary bladder cancer	0.000423	0.000935	CcSEcCtD
Iloperidone—Oedema—Epirubicin—urinary bladder cancer	0.000422	0.000933	CcSEcCtD
Iloperidone—Hypotension—Methotrexate—urinary bladder cancer	0.000421	0.000932	CcSEcCtD
Iloperidone—Infection—Epirubicin—urinary bladder cancer	0.000419	0.000927	CcSEcCtD
Iloperidone—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000414	0.000915	CcSEcCtD
Iloperidone—Tachycardia—Epirubicin—urinary bladder cancer	0.000412	0.000911	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000411	0.000909	CcSEcCtD
Iloperidone—Myalgia—Doxorubicin—urinary bladder cancer	0.000407	0.000901	CcSEcCtD
Iloperidone—Arthralgia—Doxorubicin—urinary bladder cancer	0.000407	0.000901	CcSEcCtD
Iloperidone—Paraesthesia—Methotrexate—urinary bladder cancer	0.000405	0.000895	CcSEcCtD
Iloperidone—Dyspnoea—Methotrexate—urinary bladder cancer	0.000402	0.000889	CcSEcCtD
Iloperidone—Somnolence—Methotrexate—urinary bladder cancer	0.000401	0.000887	CcSEcCtD
Iloperidone—Dry mouth—Doxorubicin—urinary bladder cancer	0.000398	0.000881	CcSEcCtD
Iloperidone—Hypotension—Epirubicin—urinary bladder cancer	0.000394	0.000872	CcSEcCtD
Iloperidone—Confusional state—Doxorubicin—urinary bladder cancer	0.000394	0.000871	CcSEcCtD
Iloperidone—Oedema—Doxorubicin—urinary bladder cancer	0.00039	0.000863	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000389	0.000861	CcSEcCtD
Iloperidone—Fatigue—Methotrexate—urinary bladder cancer	0.000389	0.00086	CcSEcCtD
Iloperidone—Infection—Doxorubicin—urinary bladder cancer	0.000388	0.000858	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000384	0.00085	CcSEcCtD
Iloperidone—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000383	0.000847	CcSEcCtD
Iloperidone—Tachycardia—Doxorubicin—urinary bladder cancer	0.000381	0.000843	CcSEcCtD
Iloperidone—Paraesthesia—Epirubicin—urinary bladder cancer	0.000379	0.000838	CcSEcCtD
Iloperidone—Dyspnoea—Epirubicin—urinary bladder cancer	0.000376	0.000832	CcSEcCtD
Iloperidone—Somnolence—Epirubicin—urinary bladder cancer	0.000375	0.00083	CcSEcCtD
Iloperidone—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000372	0.000822	CcSEcCtD
Iloperidone—Hypotension—Doxorubicin—urinary bladder cancer	0.000365	0.000807	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000364	0.000806	CcSEcCtD
Iloperidone—Fatigue—Epirubicin—urinary bladder cancer	0.000364	0.000805	CcSEcCtD
Iloperidone—Body temperature increased—Methotrexate—urinary bladder cancer	0.000356	0.000788	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000356	0.000787	CcSEcCtD
Iloperidone—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000351	0.000775	CcSEcCtD
Iloperidone—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000348	0.00077	CcSEcCtD
Iloperidone—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000348	0.000769	CcSEcCtD
Iloperidone—Somnolence—Doxorubicin—urinary bladder cancer	0.000347	0.000768	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000337	0.000745	CcSEcCtD
Iloperidone—Fatigue—Doxorubicin—urinary bladder cancer	0.000337	0.000744	CcSEcCtD
Iloperidone—Body temperature increased—Epirubicin—urinary bladder cancer	0.000334	0.000738	CcSEcCtD
Iloperidone—Asthenia—Methotrexate—urinary bladder cancer	0.000323	0.000715	CcSEcCtD
Iloperidone—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000322	0.000712	CcSEcCtD
Iloperidone—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000309	0.000683	CcSEcCtD
Iloperidone—Diarrhoea—Methotrexate—urinary bladder cancer	0.000308	0.000682	CcSEcCtD
Iloperidone—Asthenia—Epirubicin—urinary bladder cancer	0.000303	0.00067	CcSEcCtD
Iloperidone—Dizziness—Methotrexate—urinary bladder cancer	0.000298	0.000659	CcSEcCtD
Iloperidone—Diarrhoea—Epirubicin—urinary bladder cancer	0.000289	0.000639	CcSEcCtD
Iloperidone—Rash—Methotrexate—urinary bladder cancer	0.000284	0.000629	CcSEcCtD
Iloperidone—Dermatitis—Methotrexate—urinary bladder cancer	0.000284	0.000628	CcSEcCtD
Iloperidone—Asthenia—Doxorubicin—urinary bladder cancer	0.00028	0.00062	CcSEcCtD
Iloperidone—Dizziness—Epirubicin—urinary bladder cancer	0.000279	0.000617	CcSEcCtD
Iloperidone—Nausea—Methotrexate—urinary bladder cancer	0.000268	0.000592	CcSEcCtD
Iloperidone—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000267	0.000591	CcSEcCtD
Iloperidone—Rash—Epirubicin—urinary bladder cancer	0.000266	0.000588	CcSEcCtD
Iloperidone—Dermatitis—Epirubicin—urinary bladder cancer	0.000266	0.000588	CcSEcCtD
Iloperidone—Dizziness—Doxorubicin—urinary bladder cancer	0.000258	0.000571	CcSEcCtD
Iloperidone—Nausea—Epirubicin—urinary bladder cancer	0.000251	0.000554	CcSEcCtD
Iloperidone—Rash—Doxorubicin—urinary bladder cancer	0.000246	0.000544	CcSEcCtD
Iloperidone—Dermatitis—Doxorubicin—urinary bladder cancer	0.000246	0.000544	CcSEcCtD
Iloperidone—Nausea—Doxorubicin—urinary bladder cancer	0.000232	0.000513	CcSEcCtD
Iloperidone—ADRA2C—Signaling by GPCR—KRAS—urinary bladder cancer	1.99e-05	0.000123	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—ESR1—urinary bladder cancer	1.99e-05	0.000123	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—PPARG—urinary bladder cancer	1.99e-05	0.000123	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—SRC—urinary bladder cancer	1.98e-05	0.000123	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—SRC—urinary bladder cancer	1.98e-05	0.000123	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.97e-05	0.000122	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.97e-05	0.000122	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—SRC—urinary bladder cancer	1.97e-05	0.000122	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—IL2—urinary bladder cancer	1.96e-05	0.000121	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—EP300—urinary bladder cancer	1.95e-05	0.000121	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CREBBP—urinary bladder cancer	1.95e-05	0.00012	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—RHOA—urinary bladder cancer	1.94e-05	0.00012	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—IL2—urinary bladder cancer	1.93e-05	0.000119	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—IGF1—urinary bladder cancer	1.92e-05	0.000119	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CREBBP—urinary bladder cancer	1.91e-05	0.000118	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—CREBBP—urinary bladder cancer	1.91e-05	0.000118	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—EGFR—urinary bladder cancer	1.91e-05	0.000118	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CREBBP—urinary bladder cancer	1.91e-05	0.000118	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	1.91e-05	0.000118	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—CCND1—urinary bladder cancer	1.91e-05	0.000118	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—SRC—urinary bladder cancer	1.9e-05	0.000117	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—IGF1—urinary bladder cancer	1.89e-05	0.000117	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.89e-05	0.000117	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—IGF1—urinary bladder cancer	1.89e-05	0.000117	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—PTEN—urinary bladder cancer	1.89e-05	0.000117	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—CCND1—urinary bladder cancer	1.88e-05	0.000116	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—EGFR—urinary bladder cancer	1.88e-05	0.000116	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—EGFR—urinary bladder cancer	1.88e-05	0.000116	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CREBBP—urinary bladder cancer	1.87e-05	0.000116	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—ERBB2—urinary bladder cancer	1.86e-05	0.000115	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.85e-05	0.000115	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—IGF1—urinary bladder cancer	1.85e-05	0.000115	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—MMP9—urinary bladder cancer	1.85e-05	0.000115	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—ERBB2—urinary bladder cancer	1.85e-05	0.000114	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.84e-05	0.000114	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.84e-05	0.000114	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—EGFR—urinary bladder cancer	1.84e-05	0.000114	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—PTEN—urinary bladder cancer	1.84e-05	0.000114	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—PTEN—urinary bladder cancer	1.83e-05	0.000113	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—MMP9—urinary bladder cancer	1.83e-05	0.000113	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—CDKN1A—urinary bladder cancer	1.82e-05	0.000113	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	1.82e-05	0.000112	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—PTEN—urinary bladder cancer	1.82e-05	0.000112	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—KRAS—urinary bladder cancer	1.81e-05	0.000112	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—EP300—urinary bladder cancer	1.8e-05	0.000111	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—ERBB2—urinary bladder cancer	1.8e-05	0.000111	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—KRAS—urinary bladder cancer	1.78e-05	0.00011	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—MYC—urinary bladder cancer	1.78e-05	0.00011	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—MYC—urinary bladder cancer	1.77e-05	0.00011	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—KRAS—urinary bladder cancer	1.77e-05	0.00011	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—MYC—urinary bladder cancer	1.76e-05	0.000109	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—RHOA—urinary bladder cancer	1.76e-05	0.000109	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—CXCL8—urinary bladder cancer	1.76e-05	0.000109	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.76e-05	0.000109	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—EP300—urinary bladder cancer	1.76e-05	0.000109	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—CXCL8—urinary bladder cancer	1.75e-05	0.000108	CbGpPWpGaD
Iloperidone—HTR1A—Signaling by GPCR—HRAS—urinary bladder cancer	1.75e-05	0.000108	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—EP300—urinary bladder cancer	1.75e-05	0.000108	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.74e-05	0.000108	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CREBBP—urinary bladder cancer	1.74e-05	0.000108	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—KRAS—urinary bladder cancer	1.74e-05	0.000108	CbGpPWpGaD
Iloperidone—HTR2C—Signaling by GPCR—HRAS—urinary bladder cancer	1.74e-05	0.000108	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—EGFR—urinary bladder cancer	1.74e-05	0.000108	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—EGFR—urinary bladder cancer	1.74e-05	0.000107	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—RHOA—urinary bladder cancer	1.73e-05	0.000107	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—EP300—urinary bladder cancer	1.73e-05	0.000107	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—RHOA—urinary bladder cancer	1.73e-05	0.000107	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—EGFR—urinary bladder cancer	1.72e-05	0.000107	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—IGF1—urinary bladder cancer	1.72e-05	0.000106	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—EGFR—urinary bladder cancer	1.71e-05	0.000106	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—SRC—urinary bladder cancer	1.71e-05	0.000106	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—PTGS2—urinary bladder cancer	1.71e-05	0.000106	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—CXCL8—urinary bladder cancer	1.7e-05	0.000105	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—MYC—urinary bladder cancer	1.7e-05	0.000105	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—RHOA—urinary bladder cancer	1.7e-05	0.000105	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling by GPCR—HRAS—urinary bladder cancer	1.69e-05	0.000105	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—TYMS—urinary bladder cancer	1.69e-05	0.000105	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—SRC—urinary bladder cancer	1.68e-05	0.000104	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—IL2—urinary bladder cancer	1.68e-05	0.000104	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.68e-05	0.000104	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—IL2—urinary bladder cancer	1.67e-05	0.000104	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	1.67e-05	0.000103	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	1.67e-05	0.000103	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—EGFR—urinary bladder cancer	1.66e-05	0.000103	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—KRAS—urinary bladder cancer	1.64e-05	0.000102	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—KRAS—urinary bladder cancer	1.64e-05	0.000101	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—CCND1—urinary bladder cancer	1.64e-05	0.000101	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—CCND1—urinary bladder cancer	1.63e-05	0.000101	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—ERBB2—urinary bladder cancer	1.63e-05	0.000101	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—KRAS—urinary bladder cancer	1.63e-05	0.000101	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—IL2—urinary bladder cancer	1.63e-05	0.000101	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—KRAS—urinary bladder cancer	1.62e-05	0.0001	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—ERBB2—urinary bladder cancer	1.6e-05	9.92e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—ERBB2—urinary bladder cancer	1.6e-05	9.9e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.6e-05	9.9e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—MMP9—urinary bladder cancer	1.59e-05	9.85e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—CCND1—urinary bladder cancer	1.59e-05	9.82e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.59e-05	9.81e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—MMP9—urinary bladder cancer	1.58e-05	9.8e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—PTEN—urinary bladder cancer	1.58e-05	9.79e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—CDKN1A—urinary bladder cancer	1.58e-05	9.76e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—RHOA—urinary bladder cancer	1.58e-05	9.75e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—PTEN—urinary bladder cancer	1.57e-05	9.74e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1.57e-05	9.72e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—ERBB2—urinary bladder cancer	1.57e-05	9.71e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—KRAS—urinary bladder cancer	1.57e-05	9.71e-05	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	1.57e-05	9.69e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	1.56e-05	9.67e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CXCL8—urinary bladder cancer	1.55e-05	9.56e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—MMP9—urinary bladder cancer	1.54e-05	9.53e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—HRAS—urinary bladder cancer	1.54e-05	9.5e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—CDKN1A—urinary bladder cancer	1.53e-05	9.5e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—PTEN—urinary bladder cancer	1.53e-05	9.47e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—MYC—urinary bladder cancer	1.53e-05	9.46e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CXCL8—urinary bladder cancer	1.52e-05	9.41e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CXCL8—urinary bladder cancer	1.52e-05	9.39e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—HRAS—urinary bladder cancer	1.51e-05	9.35e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—EP300—urinary bladder cancer	1.51e-05	9.34e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—MYC—urinary bladder cancer	1.51e-05	9.34e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—HRAS—urinary bladder cancer	1.51e-05	9.33e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—EP300—urinary bladder cancer	1.5e-05	9.29e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—EGFR—urinary bladder cancer	1.5e-05	9.26e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CXCL8—urinary bladder cancer	1.49e-05	9.21e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—PTEN—urinary bladder cancer	1.49e-05	9.2e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—HRAS—urinary bladder cancer	1.48e-05	9.15e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—IL2—urinary bladder cancer	1.48e-05	9.14e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	1.48e-05	9.13e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—EGFR—urinary bladder cancer	1.48e-05	9.13e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—SRC—urinary bladder cancer	1.47e-05	9.08e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—EP300—urinary bladder cancer	1.46e-05	9.04e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—SRC—urinary bladder cancer	1.46e-05	9.03e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—TP53—urinary bladder cancer	1.46e-05	9.03e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—ERBB2—urinary bladder cancer	1.46e-05	9.02e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—TP53—urinary bladder cancer	1.46e-05	9.02e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—IL2—urinary bladder cancer	1.45e-05	8.99e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—IL2—urinary bladder cancer	1.45e-05	8.97e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—TP53—urinary bladder cancer	1.45e-05	8.96e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CCND1—urinary bladder cancer	1.44e-05	8.91e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—IL2—urinary bladder cancer	1.42e-05	8.8e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—SRC—urinary bladder cancer	1.42e-05	8.79e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—EP300—urinary bladder cancer	1.42e-05	8.78e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CCND1—urinary bladder cancer	1.42e-05	8.76e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CCND1—urinary bladder cancer	1.41e-05	8.74e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—KRAS—urinary bladder cancer	1.41e-05	8.74e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.41e-05	8.74e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.4e-05	8.68e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—MMP9—urinary bladder cancer	1.4e-05	8.65e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—HRAS—urinary bladder cancer	1.4e-05	8.63e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—TP53—urinary bladder cancer	1.4e-05	8.63e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—KRAS—urinary bladder cancer	1.39e-05	8.63e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—HRAS—urinary bladder cancer	1.39e-05	8.62e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.39e-05	8.62e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—PTEN—urinary bladder cancer	1.39e-05	8.6e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CCND1—urinary bladder cancer	1.39e-05	8.58e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—HRAS—urinary bladder cancer	1.38e-05	8.57e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CXCL8—urinary bladder cancer	1.38e-05	8.56e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—MMP9—urinary bladder cancer	1.38e-05	8.51e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—HRAS—urinary bladder cancer	1.37e-05	8.5e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—MMP9—urinary bladder cancer	1.37e-05	8.49e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.37e-05	8.48e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.37e-05	8.46e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—PTEN—urinary bladder cancer	1.37e-05	8.46e-05	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—PTEN—urinary bladder cancer	1.37e-05	8.45e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—PTEN—urinary bladder cancer	1.36e-05	8.44e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—PTEN—urinary bladder cancer	1.36e-05	8.43e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.36e-05	8.4e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—MMP9—urinary bladder cancer	1.35e-05	8.33e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.34e-05	8.3e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—PTEN—urinary bladder cancer	1.34e-05	8.28e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—HRAS—urinary bladder cancer	1.33e-05	8.26e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—EP300—urinary bladder cancer	1.33e-05	8.2e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—IL2—urinary bladder cancer	1.32e-05	8.18e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—MYC—urinary bladder cancer	1.32e-05	8.14e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—MYC—urinary bladder cancer	1.31e-05	8.09e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.3e-05	8.07e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—EP300—urinary bladder cancer	1.3e-05	8.07e-05	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—EP300—urinary bladder cancer	1.3e-05	8.06e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—EP300—urinary bladder cancer	1.3e-05	8.05e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—EP300—urinary bladder cancer	1.3e-05	8.04e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.29e-05	7.97e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.29e-05	7.97e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CCND1—urinary bladder cancer	1.29e-05	7.97e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—SRC—urinary bladder cancer	1.29e-05	7.97e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—EGFR—urinary bladder cancer	1.29e-05	7.96e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—EGFR—urinary bladder cancer	1.28e-05	7.92e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—EP300—urinary bladder cancer	1.28e-05	7.9e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—MYC—urinary bladder cancer	1.27e-05	7.87e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—SRC—urinary bladder cancer	1.27e-05	7.84e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—SRC—urinary bladder cancer	1.27e-05	7.83e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—TP53—urinary bladder cancer	1.26e-05	7.77e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MMP9—urinary bladder cancer	1.25e-05	7.74e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.25e-05	7.71e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—EGFR—urinary bladder cancer	1.24e-05	7.7e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—PTEN—urinary bladder cancer	1.24e-05	7.7e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—SRC—urinary bladder cancer	1.24e-05	7.68e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—TP53—urinary bladder cancer	1.24e-05	7.67e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.23e-05	7.64e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—KRAS—urinary bladder cancer	1.22e-05	7.52e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.21e-05	7.5e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—KRAS—urinary bladder cancer	1.21e-05	7.48e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—HRAS—urinary bladder cancer	1.2e-05	7.43e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.2e-05	7.41e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—EP300—urinary bladder cancer	1.19e-05	7.34e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—HRAS—urinary bladder cancer	1.19e-05	7.33e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—KRAS—urinary bladder cancer	1.18e-05	7.28e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—MYC—urinary bladder cancer	1.15e-05	7.14e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—SRC—urinary bladder cancer	1.15e-05	7.14e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.15e-05	7.11e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.14e-05	7.05e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—MYC—urinary bladder cancer	1.14e-05	7.03e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—MYC—urinary bladder cancer	1.13e-05	7.01e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—EGFR—urinary bladder cancer	1.13e-05	6.99e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—MYC—urinary bladder cancer	1.11e-05	6.88e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.11e-05	6.88e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—EGFR—urinary bladder cancer	1.11e-05	6.88e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—EGFR—urinary bladder cancer	1.11e-05	6.86e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—EGFR—urinary bladder cancer	1.09e-05	6.73e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—TP53—urinary bladder cancer	1.08e-05	6.68e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—TP53—urinary bladder cancer	1.07e-05	6.65e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—KRAS—urinary bladder cancer	1.07e-05	6.6e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—KRAS—urinary bladder cancer	1.05e-05	6.5e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—KRAS—urinary bladder cancer	1.05e-05	6.48e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—TP53—urinary bladder cancer	1.05e-05	6.47e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MYC—urinary bladder cancer	1.03e-05	6.4e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—HRAS—urinary bladder cancer	1.03e-05	6.39e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—KRAS—urinary bladder cancer	1.03e-05	6.36e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—HRAS—urinary bladder cancer	1.03e-05	6.36e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—EGFR—urinary bladder cancer	1.01e-05	6.26e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—HRAS—urinary bladder cancer	1e-05	6.18e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PTEN—urinary bladder cancer	9.69e-06	6e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—KRAS—urinary bladder cancer	9.55e-06	5.91e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—TP53—urinary bladder cancer	9.48e-06	5.87e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	9.42e-06	5.83e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—TP53—urinary bladder cancer	9.33e-06	5.77e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—TP53—urinary bladder cancer	9.31e-06	5.76e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—EP300—urinary bladder cancer	9.24e-06	5.72e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PPARG—urinary bladder cancer	9.24e-06	5.72e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—TP53—urinary bladder cancer	9.14e-06	5.65e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—HRAS—urinary bladder cancer	9.07e-06	5.61e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—HRAS—urinary bladder cancer	8.92e-06	5.52e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—HRAS—urinary bladder cancer	8.91e-06	5.51e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	8.87e-06	5.49e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—HRAS—urinary bladder cancer	8.74e-06	5.41e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—TP53—urinary bladder cancer	8.49e-06	5.25e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PTEN—urinary bladder cancer	8.21e-06	5.08e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—HRAS—urinary bladder cancer	8.12e-06	5.02e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—EP300—urinary bladder cancer	7.83e-06	4.85e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	7.27e-06	4.5e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PTEN—urinary bladder cancer	6.34e-06	3.92e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—EP300—urinary bladder cancer	6.04e-06	3.74e-05	CbGpPWpGaD
